We scan new podcasts and send you the top 5 insights daily.
In Dr Hussain’s case, two prominent gynecologic oncologists suggested hospice without mentioning avutometinib plus defactinib. Banerjee notes the FDA accelerated approval and NCCN listing are over a year old and calls for multi-prong education for all clinicians across the clinical oncology team, much like the BRCA/PARP rollout.
Oncologists treating GU cancers are learning best practices for managing side effects of newer drugs like TDXD and Capivasertib from breast cancer experts, who have a longer history and more granular knowledge of using these agents effectively and safely.
While initial response rates are similar between the Avutometinib/Defactinib doublet and single-agent Trametinib, the doublet provides double the progression-free survival (PFS). Its remarkable duration of response (over 30 months) indicates superior long-term disease control.
Banerjee says a patient from her phase 1 study stayed on avutometinib plus defactinib for about five years, showing durable efficacy and tolerability. She stresses it is active treatment rather than maintenance and would continue it in her practice until progression unless side effects limit tolerability.
Banerjee says with a KRAS mutation at progression she would likely choose avutometinib plus defactinib in the US, but for KRAS wild-type disease she would try trametinib or binimetinib first. She considers folate-receptor ADC evidence in LGSOC still anecdotal and reserves mirvetuximab after MEK/RAF therapy.
For BRAF V600E low-grade serous ovarian cancer patients who progress on dabrafenib/trametinib, clinicians can appeal for the KRAS-approved combination avutametinib/defactinib. This strategy is based on evidence of the drug's activity in KRAS wild-type patients, offering a rational off-label option.
A patient who failed trametinib later responded to the avutametinib/defactinib combination. This suggests that resistance to one MEK inhibitor does not preclude a response to a different agent or combination targeting the same pathway, offering a viable later-line treatment strategy.
While the avutometanib/defactinib combination is newly approved for KRAS-mutated ovarian cancer, its significant toxicity profile—causing up to a third of patients to stop treatment—creates a clear clinical need for agents like specific KRAS inhibitors that may offer similar efficacy with better tolerability.
Susanna Banerjee shared that the single-arm Chameleon trial evaluates upfront avutometinib, defactinib, and letrozole to downsize bulky or inoperable disease. Because low-grade serous cancer responds poorly to frontline chemotherapy, targeted shrinking aims to give advanced patients the opportunity to undergo complete surgical resection.
A podcast host notes that gynecologic oncologists were unfamiliar with new TKI approvals in lung cancer. This highlights a critical knowledge gap between subspecialties, which can delay understanding of shared drug side effects and adoption of relevant therapeutic strategies across different cancer types.
The RAMP-201 trial showed the combination of Avutometinib and Defactinib achieved a 25% response rate even in patients who had progressed on or were intolerant of prior single-agent MEK inhibitors. This establishes the doublet as an effective subsequent line of therapy in a resistant population.